Luboš Petruželka

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Breast Oncology, Long-term Effects, Medicine +7

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Franck Pagès, Bernhard Mlecnik, Florence Marliot et al. · The Lancet · 2018 · 2K citations

Prognostic Biomarkers, Oncology, International Validation +12

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · Journal of Clinical Oncology · 2010 · 630 citations · Full text

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

Petr Zatloukal, Luboš Petruželka, Milada Zemanová et al. · Lung Cancer · 2004 · 430 citations

Radiation Therapy, Randomized Study, Medicine +7